PARDES BIOSCIENCES INC (PRDS) Stock Price, Quote, News and Overview
NASDAQ:PRDS - Nasdaq - US69945Q1058 - Common Stock - Currency: USD
PRDS Quote, Performance and Key Statistics
2.16
0 (0%)
The current stock price of PRDS is 2.16 USD. In the past month the price increased by 2.37%. In the past year, price decreased by -40%.
PRDS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About PRDS
Company Profile
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The company went IPO on 2021-02-17. The firm is focused on discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. Its lead product candidate, pomotrelvir, which targets the coronavirus disease (COVID-19). Pomotrelvir is in clinical development to treat COVID-19 in adult and pediatric patients. The Company, by leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, it has discovered and is developing novel product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. Its lead product candidate, pomotrelvir, inhibits the main coronaviral cysteine protease (Mpro), a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. Inhibiting Mpro prevents the liberation and assembly of the viral replication complex, blocking replication before it begins.
Company Info
PARDES BIOSCIENCES INC
2173 Salk Avenue, Suite 250, Pmb#052
Carlsbad CALIFORNIA US
Employees: 57
Company Website: https://www.pardesbio.com/
Phone: 14156498758.0
PARDES BIOSCIENCES INC / PRDS FAQ
What is the stock price of PARDES BIOSCIENCES INC today?
The current stock price of PRDS is 2.16 USD.
What is the ticker symbol for PARDES BIOSCIENCES INC stock?
The exchange symbol of PARDES BIOSCIENCES INC is PRDS and it is listed on the Nasdaq exchange.
On which exchange is PRDS stock listed?
PRDS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PARDES BIOSCIENCES INC stock?
6 analysts have analysed PRDS and the average price target is 1.27 USD. This implies a price decrease of -40.97% is expected in the next year compared to the current price of 2.16. Check the PARDES BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PARDES BIOSCIENCES INC worth?
PARDES BIOSCIENCES INC (PRDS) has a market capitalization of 133.95M USD. This makes PRDS a Micro Cap stock.
How many employees does PARDES BIOSCIENCES INC have?
PARDES BIOSCIENCES INC (PRDS) currently has 57 employees.
What are the support and resistance levels for PARDES BIOSCIENCES INC (PRDS) stock?
PARDES BIOSCIENCES INC (PRDS) has a support level at 2.15 and a resistance level at 2.17. Check the full technical report for a detailed analysis of PRDS support and resistance levels.
Should I buy PARDES BIOSCIENCES INC (PRDS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRDS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRDS, evaluating the profitability, health, valuation and growth aspects
- PARDES BIOSCIENCES INC (PRDS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PARDES BIOSCIENCES INC (PRDS) Sales and EPS estimates to see what analysts future expectations are.
- PARDES BIOSCIENCES INC (PRDS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PARDES BIOSCIENCES INC (PRDS) Insider and Institutional Ownership to learn about the owners and their transactions.
- PARDES BIOSCIENCES INC (PRDS) Stock Chart to make your own analysis
- PARDES BIOSCIENCES INC (PRDS) Latest news and press-releases to stay up to date.
Does PARDES BIOSCIENCES INC (PRDS) stock pay dividends?
PRDS does not pay a dividend.
When does PARDES BIOSCIENCES INC (PRDS) report earnings?
PARDES BIOSCIENCES INC (PRDS) will report earnings on 2023-11-06, after the market close.
What is the Price/Earnings (PE) ratio of PARDES BIOSCIENCES INC (PRDS)?
PARDES BIOSCIENCES INC (PRDS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.29).
PRDS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PRDS. When comparing the yearly performance of all stocks, PRDS is a bad performer in the overall market: 72.9% of all stocks are doing better.
PRDS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRDS. PRDS has a great financial health rating, but its profitability evaluates not so good.
PRDS Financial Highlights
Over the last trailing twelve months PRDS reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS increased by 12.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PRDS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to PRDS. The Buy consensus is the average rating of analysts ratings from 6 analysts.